OnCo
technologiesTechnologyEstablished

Payload-linker synthesis (high-potency API)

Making the microgram-potent toxins inside ADCs, in facilities built so a speck of dust cannot harm a worker.

Camptothecin derivatives (exatecan, DXd), auristatins (MMAE/MMAF), maytansinoids (DM1/DM4), and PBD dimers are synthesised under OEB 5/6 containment by specialists (Lonza, MilliporeSigma, WuXi STA, Piramal, Sterling, Ajinomoto Bio-Pharma, Levena, Cerbios, Kelun in-house) and sold as ready-to-conjugate linker-payloads. Supply is a gating factor for the hundreds of ADCs in development.

Generic schematic · not to scale · placeholder for the adcs front
Antibody (Fc) · Payload on cleavable linker (DAR 8) · Antigen-binding arm

How it works

Multi-step synthesis and purification of cytotoxic small molecules and linkers under engineered containment, with occupational exposure limits in the nanogram range.

Strengths
  • Standardised, reusable linker-payload building blocks
Limitations
  • Few licensed sites
  • Long lead times
  • IP encumbrance on best payloads

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Payload-linker synthesis" OR ABSTRACT:"Payload-linker synthesis" OR TITLE:"high-potency API" OR ABSTRACT:"high-potency API") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Payload-linker synthesis (high-potency API), not a curated reading list.

Connected

8top